The first experiment analyzed differentially expressed genes in 14 diagnostic AML samples (Supplementary Table 1) with low versus high WT1 levels, using Affymetrix GeneChip® HG-U133 Plus 2.0 microarrays. This evidence concerns the gene WT1 and acute myeloid leukemia.